A recent study has found that one in four men admitted to hospital with acute urinary retention (AUR) dies within a year.
The study involved 176,046 men over 45 who were admitted to hospital with Acute urinary retention (AUR).
Prostate Cancer: Treatment Options
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.
Advertisement
AUR is the sudden inability to pass urine and is often a progression of benign prostatic hyperplasia (an increase in size of the prostate in middle-aged and elderly men which can interfere with the normal flow of urine). It is a medical emergency and is thought to be linked to the presence of other disorders such as high blood pressure and diabetes.
The researchers discovered the risk of death in men after acute urinary retention was close to that seen in patients who had a broken hip. The problem was set to worsen as the population ages, warn the researchers.
So in order to investigate the risk of death associated with AUR, the researchers analyzed data on all men aged over 45 years who were admitted to NHS hospitals in England with a first episode of AUR between 1998 and 2005.
Mortality in the first year after AUR was compared to mortality among the general male population of similar age. Mortality among these men was very high. One in seven men with spontaneous AUR (no evidence of precipitating factors other than benign prostatic hyperplasia) and one in four with precipitated AUR died in the first year.
The authors found that the risk of death increased with age and the presence of other disorders (comorbidity). Consequently, about half the men aged over 85 years with comorbid conditions died within the first year after AUR.
Overall mortality at one year in men admitted to hospital for AUR was two to three times higher than for the general male population. However, in men aged between 45 and 54 years with precipitated AUR, there was an almost 24-fold increase in mortality compared to the general population.
The researchers thus concluded that mortality of hospitalized men with AUR was high and increased strongly with age and the presence of other conditions. As a result, patients with AUR may benefit from urgent multi-disciplinary care to identify and treat comorbidity early.
The study supports the call for multidisciplinary care in these men and is published on bmj.com.
Source: ANI
SRM/C
Advertisement
So in order to investigate the risk of death associated with AUR, the researchers analyzed data on all men aged over 45 years who were admitted to NHS hospitals in England with a first episode of AUR between 1998 and 2005.
Mortality in the first year after AUR was compared to mortality among the general male population of similar age. Mortality among these men was very high. One in seven men with spontaneous AUR (no evidence of precipitating factors other than benign prostatic hyperplasia) and one in four with precipitated AUR died in the first year.
The authors found that the risk of death increased with age and the presence of other disorders (comorbidity). Consequently, about half the men aged over 85 years with comorbid conditions died within the first year after AUR.
Overall mortality at one year in men admitted to hospital for AUR was two to three times higher than for the general male population. However, in men aged between 45 and 54 years with precipitated AUR, there was an almost 24-fold increase in mortality compared to the general population.
The researchers thus concluded that mortality of hospitalized men with AUR was high and increased strongly with age and the presence of other conditions. As a result, patients with AUR may benefit from urgent multi-disciplinary care to identify and treat comorbidity early.
The study supports the call for multidisciplinary care in these men and is published on bmj.com.
Source: ANI
SRM/C
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Menīs Health News
Prostate cancer mutations targeting PI3K signaling are greatly influenced by PLEKHS1, a protein, enhances cancer drug therapy efficiency.
A substantial reduction in mortality risk was found in older men taking medications for lower urinary tract symptoms (LUTS).
Men's human papillomavirus (HPV) infections underscore the importance of their participation in efforts to reduce HPV-related diseases in all genders.
Men who received active Optilume treatment demonstrated more significant improvement in symptoms related to benign prostatic hyperplasia.
Investigation of sperm formation and its molecular intricacies reveals a potential connection between infertility and alterations in sperm amino acids.
